fatty diacid chain comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-22. Numbers and descriptions here follow the published literature rather than marketing material.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
In the war's aftermath, the Iraqi government suppressed a series of uprisings until 5 April 1991. Coalition countries responded by establishing two no-fly zones over Iraq's north and south. The United Nations Special Commission sought to end Iraq's weapons of mass destruction programs. In 2003, another US-led coalition invaded and occupied Iraq, beginning the Iraq War. The conflict's environmental impact included Iraqi forces causing over six hundred oil well fires and the largest oil spill in history until that point. US bombing and demolition of Iraqi chemical weapons facilities were concluded to be the primary cause of Gulf War syndrome, experienced by over 40% of US veterans.
=== Prokaryotes expression vector === Promoter - commonly used inducible promoters are promoters derived from lac operon and the T7 promoter. Other strong promoters used include Trp promoter and Tac-Promoter, which are a hybrid of both the Trp and Lac Operon promoters. Ribosome binding site (RBS) - follows the promoter, and promotes efficient translation of the protein of interest. Translation initiation site - Shine-Dalgarno sequence enclosed in the RBS, 8 base-pairs upstream of the AUG start codon.
The New York Times described Harris's economic policy as embracing "the idea that the federal government must act aggressively to foster competition and correct distortions in private markets". Harris proposed raising taxes on corporations and high-earners to fund services for the lower and middle classes and reduce the deficit. Harris stated she supported increasing the top tier capital gains tax rate to 28%, up from 20% and lower than Biden's proposed 39.6%. Harris stated her support for a Billionaire Minimum Income Tax, increasing the tax on stock buybacks to 4%, and a ten-fold tax reduction for small business ranging from $5,000 to $50,000 in relief. Harris also supported efforts to create a tax on unrealized gains for those with more than a $100 million in net worth if they do not pay a minimum 25% tax rate on their income inclusive of unrealized gains so long as 80% of said wealth is in tradeable assets. The plan would impact a small percentage of the wealthy in the United States, and Axios reported most tech founders and investors would be spared. Harris also announced support for restoring the corporate tax rate to 28% among several other tax proposals to raise taxes and close loopholes for corporations and the wealthy that would bring in $5 trillion in additional revenue over 10 years. Harris proposed tax breaks to companies delivering economic benefit, such as manufacturing technologies that mitigate climate change and building affordable housing, and proposed a ban on corporate price gouging to "help the food industry become more competitive".
The two substrates of this enzyme are L-arabinose and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are L-arabino-1,4-lactone, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-arabinose:NAD+ 1-oxidoreductase. This enzyme participates in ascorbate and aldarate metabolism.
Since 2009, Carrey's work has included a leading role in Glenn Ficarra and John Requa's I Love You Phillip Morris, premiering in January 2009 at the Sundance Film Festival before receiving a wide release in February 2010. Carrey portrayed Steven Jay Russell, a con artist, imposter, and multiple prison escapee who falls in love with his fellow inmate, Phillip Morris (played by Ewan McGregor). The film received largely positive reviews, with Damon Wise of The Times giving the film four stars out of five, stating, "I Love You Phillip Morris is an extraordinary film that serves as a reminder of just how good Carrey can be when he's not tied into a generic Hollywood crowd-pleaser. His comic timing remains as exquisite as ever." For the first time in his career, Carrey portrayed multiple characters in Disney's 3D animated take on the classic Charles Dickens tale, A Christmas Carol (2009), voicing Ebenezer Scrooge and the Ghosts of Christmas Past, Present, and Future. Directed by Robert Zemeckis, the film also starred Robin Wright Penn, Bob Hoskins, Colin Firth, Gary Oldman, and Cary Elwes. The film received decent reviews and was a financial success. Carrey landed the lead role in Mr. Popper's Penguins (2011), playing Tom Popper Jr., a realtor who becomes the caretaker of a family of penguins. The film received a mixed reception upon release.
Sources: en.wikipedia.org
PT-00114, also known as TCAP-1, is a corticotropin-releasing hormone (CRH) inhibitor which is under development for the treatment of generalized anxiety disorder, major depressive disorder, opioid-related disorders, post-traumatic stress disorder (PTSD), and mood disorders. It is taken by subcutaneous injection. The drug is a synthetic analogue of the teneurin C-terminal associated peptides (TCAP) and is a 41-amino acid peptide. It has been reported to produce anxiolytic-like effects in animals, among other effects. PT-00114 is under development by Protagenic Therapeutics and Charles River Laboratories. As of August 2025, it is in phase 1/2 clinical trials for generalized anxiety disorder, major depressive disorder, opioid-related disorders, and PTSD and is in phase 1 trials for mood disorders. It is or was also under development for the treatment of other anxiety and depressive disorders as well as of impulse control disorders and neurodegenerative disorders, but no recent development has been reported for these indications.
isoelectric point (pH(I), pI) Also isoelectric pH. The pH at which a particular molecule, often a protein, carries no net electrical charge, i.e. at which it is electrically neutral in the statistical mean. The concentration of protons (H+) in the surrounding environment affects how readily molecules gain or lose protons and thus their electrical properties. When the environmental pH is greater than the molecule's pI, the molecule is negatively charged, and when the pH is less than the pI, it is positively charged. Isoelectric point is therefore important for determining the behavior of molecules exposed to electric fields, as in electrophoresis and ion chromatography. Proteins are least soluble at their isoelectric points because electrically neutral species do not repulse each other with electrostatic forces, such that they tend to aggregate and precipitate out of solution.
== Global policy == He was one of the signatories of the agreement to convene a convention for drafting a world constitution. As a result, for the first time in human history, a World Constituent Assembly convened to draft and adopt a Constitution for the Federation of Earth.
=== GLC (1981–1985) === The equivalent American Mazda GLC (Great Little Car) appeared in the 1981 model year, although the rear-wheel drive wagon also continued to be offered. It was only offered with a single engine – the twin-barrel 1.5-litre with 68 hp (51 kW)—and lasted through 1985, after which it was replaced by the next-generation Mazda 323. With this, the GLC nameplate was retired. The BD was the only front-wheel drive Mazda vehicle using the GLC name. Originally it was offered with three- or five-door bodywork, in standard, Custom, Custom L, or Sport equipment levels. The five-door only came as a Custom and was sold only in Hawaii and Puerto Rico. All cars received exposed rectangular sealed-beam units. The later four-door saloon, introduced for 1983, was available in Custom, Custom L, and Sport models. The Sport received blacked out trim, a steering wheel borrowed from the RX-7, full instrumentation, and a special rear interior which closely integrates the side trim with the rear seat design – an early iteration of a design philosophy taken to its extreme with the 1988 Persona and the 1990 Eunos Cosmo. Unlike the sporting 323s in other markets, the Sport only received special hubcaps, rather than alloy wheels. For 1982, the Sport was made to live up to its name a little bit more, with the installation of a front anti-roll bar and cast aluminum wheels. The five-door GLC gained a fully carpeted trunk for 1982.
== Myths == A common myth among radar and microwave communication workers is that the exposure of the genital area to microwaves renders a man sterile for about a day. The power density necessary for this effect is however sufficient to also cause permanent damage.
Sources: en.wikipedia.org
Gram-positive bacteria: Staphylococcus aureus (beta-lactamase and non-beta-lactamase producing), Staphylococcus epidermidis (beta-lactamase and non-beta-lactamase producing), Staphylococcus saprophyticus (beta-lactamase and non-beta-lactamase producing), Enterococcus faecalis, Streptococcus pneumoniae, Streptococcus pyogenes, and Streptococcus viridans. Gram-negative bacteria: Haemophilus influenzae (beta-lactamase and non-beta-lactamase producing), Moraxella catarrhalis (beta-lactamase and non-beta-lactamase producing), Escherichia coli (beta-lactamase and non-beta-lactamase producing), Klebsiella spp. (all known species are beta-lactamase producing), Proteus mirabilis (beta-lactamase and non-beta-lactamase producing), Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Morganella morganii, and Neisseria gonorrhoeae (beta-lactamase and non-beta-lactamase producing). Anaerobes: Clostridium spp., Peptococcus spp., Peptostreptococcus spp, Bacteroides spp. including B. fragilis. Gynecological Infections Ampicillin/sulbactam can be used to treat gynecological infections caused by beta-lactamase producing strains of E. coli, and Bacteroides spp. (including B. fragilis). Bone and joint infections Ampicillin/sulbactam can be used in the treatment of bone and joint infections caused by susceptible beta-lactamase producing bacteria. Intra-abdominal infections Ampicillin/sulbactam can be used to treat intra-abdominal infections caused by beta-lactamase producing strains of E. coli, Klebsiella spp. (including K. pneumoniae), B. fragilis, and Enterobacter spp.
===== Lipid nanoparticles ===== Lipid nanoparticles (LNPs) are based on liposome-like structures that are typically made of an aqueous center surrounded by a lipid shell. A subset of liposomal structures used for delivery drugs to tissues rest in large unilamellar vesicles (LUVs) which may be 100 nm in size. LNP delivery mechanisms have become an increasing source of encasing nucleic acids and may include plasmids, CRISPR and mRNA. The first approved use of lipid nanoparticles as a drug delivery mechanism began in 2018 with the siRNA drug patisiran, developed by Alnylam Pharmaceuticals. Dicerna Pharmaceuticals, Persomics, Sanofi and Sirna Therapeutics also worked to bring RNAi therapies to market. Other recent applications include two FDA approved COVID-19 vaccines: mRNA-1273, developed by Moderna. and BNT162b, developed by a collaboration between Pfizer and BioNtech. These two vaccines use lipid nanoparticles to deliver antigen mRNA. Encapsulating the mRNA molecule in lipid nanoparticles was a critical breakthrough for producing viable mRNA vaccines, solving a number of key technical barriers in delivering the mRNA molecule into the host cell as distributed through apolipoprotein E (apoE) in the low-density lipoprotein receptor (LDLR). In December 2020, Novartis announced that positive results from phase III efficacy studies deemed inclisiran was a treatment for heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD).
To perform a selective separation, the distribution ratio of the solute to be extracted must be greater than one, whereas that belonging to the solutes which remain in the aqueous feed must be lower than one. This always yields a separation factor SF > 1. Generally, the effects of acidity and temperature on distribution ratios and the separation factor are investigated because the main species with actinides and lanthanides could be prone to decomplexation upon increasing acidity due to protonation of the ligand or due to increasing temperature. The thermodynamic effects are usually investigated by performing extraction tests at increasing temperature. Furthermore, thermodynamics studies can assess the several alkyl chains of a ligand on its complexation properties towards minor actinides than lanthanides. The extraction processes are based on the complexation of metal ions with lipophilic or hydrophilic ligands. The extracting agent forms a coordination complex with the metal ion as a product of a Lewis acid-base reaction. Ligands are named bases (donors) and contain at least one electron lone pair to donate to metal ions named acids (acceptors). Metal cations in the aqueous feed raffinate are generally solvated by coordinating water molecules through the donor oxygen atoms to form aquo ions
=== Second stranding === Between January 9 and January 15, a storm tide dragged the carcass out to sea, but it washed ashore again on the next tide, on Crescent Beach, two miles to the south of its original location. Webb sent photographs of the mass, along with a description, to Joel Asaph Allen of the Museum of Comparative Zoology at Harvard. Allen apparently did not respond, but Webb's letter came to the attention of Prof. Addison Emery Verrill of Yale, at that time the foremost authority on cephalopods in the country. At first, Verrill suggested the carcass might represent the remains of a giant squid. In the January 1897 issue of the American Journal of Science he wrote:
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.